Andy Chen
Stock Analyst at Wolfe Research
(4.50)
# 880
Out of 5,182 analysts
46
Total ratings
60%
Success rate
23.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Initiates: Outperform | $7 | $2.08 | +236.54% | 1 | Apr 9, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $48 | $13.92 | +244.83% | 1 | Apr 9, 2026 | |
| DNTH Dianthus Therapeutics | Initiates: Outperform | $98 | $87.39 | +12.14% | 1 | Apr 9, 2026 | |
| PHVS Pharvaris | Initiates: Outperform | $42 | $28.58 | +46.96% | 1 | Apr 9, 2026 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $12 → $24 | $17.18 | +39.70% | 4 | Mar 23, 2026 | |
| VERA Vera Therapeutics | Upgrades: Outperform | $88 | $37.69 | +133.48% | 3 | Mar 11, 2026 | |
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $85.61 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $28.58 | +74.95% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $84.91 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $430.29 | +27.36% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $780.25 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $13.63 | - | 3 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $40.94 | - | 1 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Peer Perform | n/a | $305.54 | - | 3 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $73.28 | -33.13% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $20.30 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $58.88 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $38.33 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $69.03 | -71.03% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $18.19 | +4.45% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $94.65 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $33.29 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $512.39 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.73 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $73.27 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $48.79 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $27.41 | -37.98% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $135.17 | -68.93% | 1 | Feb 15, 2024 |
Palisade Bio
Apr 9, 2026
Initiates: Outperform
Price Target: $7
Current: $2.08
Upside: +236.54%
Avalo Therapeutics
Apr 9, 2026
Initiates: Outperform
Price Target: $48
Current: $13.92
Upside: +244.83%
Dianthus Therapeutics
Apr 9, 2026
Initiates: Outperform
Price Target: $98
Current: $87.39
Upside: +12.14%
Pharvaris
Apr 9, 2026
Initiates: Outperform
Price Target: $42
Current: $28.58
Upside: +46.96%
MoonLake Immunotherapeutics
Mar 23, 2026
Upgrades: Outperform
Price Target: $12 → $24
Current: $17.18
Upside: +39.70%
Vera Therapeutics
Mar 11, 2026
Upgrades: Outperform
Price Target: $88
Current: $37.69
Upside: +133.48%
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $85.61
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $28.58
Upside: +74.95%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $84.91
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $430.29
Upside: +27.36%
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $780.25
Upside: -
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $13.63
Upside: -
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $40.94
Upside: -
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $305.54
Upside: -
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $73.28
Upside: -33.13%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $20.30
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $58.88
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $38.33
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $69.03
Upside: -71.03%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $18.19
Upside: +4.45%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $94.65
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $33.29
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $512.39
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $13.73
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $73.27
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $48.79
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $27.41
Upside: -37.98%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $135.17
Upside: -68.93%